Regorafenib for recurrent high-grade glioma: a unicentric retrospective analysis of feasibility, efficacy, and toxicity.

Neurosurg Rev · 2022 · PMC9492606 · PMID 35725846

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

showed a trendp = 0.0900so close (0.05 < p ≤ 0.1)

Patients who received regorafenib in 2nd line versus 3rd or higher line of treatment showed a trend towards improved OS, without statistical significance ( p = 0.0900) (Fig. 2D ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.